Vaxcyte is transitioning from a single-product biotech to a commercial vaccine platform with its 31-valent pneumococcal conjugate vaccine, VAX-31, which offers broader serotype coverage than competitors. The vaccine is currently in pivotal Phase 3 trials for adults and Phase 2 trials for infants. Vaxcyte's strong financial position, including over $2.4 billion in cash and a completed manufacturing facility, supports simultaneous late-stage development and commercial readiness. Key upcoming milestones include the OPUS-1 Phase 3 trial results expected in Q4 2026 and additional adult and infant data in 2027, positioning Vaxcyte as a potential leader in next-generation vaccines.
Perplexity AI CEO Aravind Srinivas shared lessons from Nvidia's Jensen Huang and Tesla's Elon Musk, highlighting Huang's mindset of running Nvidia as if it could fail within 30 days despite its $5 trillion valuation and advanced technology. Srinivas ...
Meta Platforms introduced an AI-powered feature called "AI Mode" within Facebook Search, which uses Meta's AI model Muse Spark to provide answers from public content rather than traditional search results. This innovation could generate over $10 bill...
Cuprina Holdings shares surged 111.84% intraday following FDA 510(k) clearance for its MEDIFLY Maggots wound care product, the first maggot debridement therapy using Lucilia cuprina species approved in the U.S. The product treats non-healing necrotic...
Cortea secured €12 million in funding led by Dawn Capital to develop AI-powered Audit Quality Agents that review audit reports and financial statements, identifying errors and inconsistencies before sign-off. These tools help audit firms improve qual...
Cortea secured €12 million in seed funding led by Dawn Capital to develop AI tools that enhance audit quality without compromising accuracy. Their Audit Quality Agents review audit reports and financial statements to detect inconsistencies and errors...
